Open AccessA Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa
Author(s) -
Anisa Mosam,
F Shaik,
Thomas S. Uldrick,
Tonya Esterhuizen,
Gerald Friedland,
David T. Scadden,
Jamila Aboobaker,
Hoosen Coovadia
Publication year - 2012
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e318251aedd
Subject(s) - medicine , nevirapine , lamivudine , vincristine , zidovudine , randomized controlled trial , chemotherapy , surgery , viral load , sarcoma , stavudine , immunology , antiretroviral therapy , viral disease , human immunodeficiency virus (hiv) , cyclophosphamide , pathology , hepatitis b virus , virus
The optimal approach to HIV-associated Kaposi sarcoma (HIV-KS) in sub-Saharan Africa is unknown. With large-scale rollout of highly active antiretroviral therapy (HAART) in South Africa, we hypothesized that survival in HIV-KS would improve and administration of chemotherapy in addition to HAART would be feasible and improve KS-specific outcomes.